Treatment News : FDA Turns Down Prezista 800 mg Tablet - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » May 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


May 30, 2012

FDA Turns Down Prezista 800 mg Tablet

by Tim Horn

The U.S. Food and Drug Administration has not approved Janssen Therapeutics’ application to market an 800 milligram (mg) tablet version of its protease inhibitor Prezista (darunavir), The Associated Press reports

Janssen plans to respond to the FDA’s letter regarding the 800 mg Prezista application as quickly as possible, in an effort to address lingering approval issues.

Though Pam Van Houten, a Janssen spokesperson, declined to discuss the specific issues in the FDA letter when contacted by AIDSmeds, the company does not expect additional clinical trials will be necessary to address the FDA’s feedback.

For people living with HIV not harboring resistance mutations to Prezista, the protease inhibitor can still be taken once daily at a dose of 800 mg—in the form of two 400 mg tablets—combined with 100 mg Norvir (ritonavir).

Janssen is developing the 800 mg tablet to allow people taking once-daily Prezista to reduce their pill volume.

“I do want to make sure it is clear that this letter is only for the 800 mg tablet,” Van Houten said. “It doesn’t impact the 800 mg indication. Patients can continue taking two 400 mg tablets for the once-daily indication.”

Search: prezista, darunavir, 800 mg, tablet, simplification, fda, rejection

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (2 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.